Trial Profile
An Open-label, Phase III Clinical Trial to Evaluate the Safety and Antiviral Activity of Clevudine in Chronic Hepatitis B Patients Who Have Completed the L-FMAU-301 or L-FMAU-302 Trials
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Clevudine (Primary)
- Indications Hepatitis B
- Focus Therapeutic Use
- Sponsors Bukwang Pharmaceutical
- 08 Jul 2008 According to a Pharmasset media release, 80 percent of HBeAg- patients had undetectable HBV DNA 12 weeks after completing a 48-week course of therapy.
- 16 Nov 2006 New trial record.